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Abstract Autonomously functioning thyroid nodules
(AFTN) are known to receive an increased blood influx
necessary to sustain their high rate of growth and hormone
production. Here, we investigated the expression of
hematic and lymphatic vases in a series of 20 AFTN
compared with the contralateral non-tumor tissues of the
same patients, and the transcript levels of proteins involved
in the control of vascular proliferation, including the vas-
cular endothelial growth factor (VEGF) and platelet-
derived growth factors (PDGF) and their receptors and the
endothelial nitric oxide synthase (eNOS). In parallel, the
expression of the differentiation markers sodium/iodide
symporter (NIS), thyroperoxidase (TPO), thyroglobulin
(Tg), and TSH receptor (TSHR) was also investigated. The
data were further analyzed comparing subgroups of tumors
with or without mutations in the TSHR gene. Analysis by
means of CD31 and D2-40 immunostaining showed in
AFTN an increased number of hematic, but not lymphatic,
vessels in parallel with an enhanced proliferation rate
shown by increased Ki67 staining. Quantitative RT-PCR
analysis revealed an increase of VEGF, VEGFR1 and 2,
PDGF-A, PDGF-B, and eNOS expression in tumor versus
normal tissues. Also, higher transcript levels of NIS, TPO,
and Tg were detected. Comparison of the two subgroups of
samples revealed only few differences in the expression of
the genes examined. In conclusion, these data demonstrate
an increased expression of angiogenesis-related factors
associated with an enhanced proliferation of hematic, but
not lymphatic, vessels in AFTNs. In this context, the
presence of TSHR mutations may only slightly influence
the expression of pro-angiogenic growth factors.
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Introduction
Autonomously functioning thyroid nodules (AFTN) are the
second most frequent cause of hyperthyroidism and thus,
they can have repercussions on the cardiovascular system
and skeleton as well as on other organs and systems [1]. The
presence of activating mutations of the TSH receptor
(TSHR) gene has been reported in these tumors, when pre-
senting as sporadic disease occurring either as single or in a
multinodular goiter, in a sporadic or familial disease [2, 3].
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More than 30 different amino acid substitutions have been
described so far, and while their pathogenic role for the
growth and function of the autonomous nodule is clearly
established, the contribution of other factors to the acquisi-
tion of the full phenotype of the disease [3, 4] is still debated.
Indeed, activating TSHR mutations have been also described
in other thyroid diseases as hyperfunctioning carcinomas or
‘‘compensated’’ familial hypothyroidism [5, 6].
An increased blood supply provided by enhanced vas-
cularization is a known feature of these tumors. Indeed,
studies in small series of toxic adenomas have revealed
changes in the secretion or expression of the vascular
endothelial growth factor (VEGF) [7, 8] and platelet-
derived growth factors (PDGF) [9], but the global gene
expression profile of these factors and their receptors in
these tumors has never been investigated. Moreover, there
are no data regarding the influence of the TSH receptor
mutations on the tumor vascularization and the expression
of the angiogenic factors as well as their relationship with
other markers of thyrocyte differentiation such as sodium
iodide symporter (NIS), TSHR, Thyroglobulin (Tg), and
Thyroperoxidase (TPO).
Herein, we analyzed the microvessel and lymphatic
vessel densities in a series of autonomously functioning
thyroid adenomas including tumors with and without
activating mutations of the TSH receptor gene. We also
investigated the gene expression of the following: the
growth factors VEGF-A, PDGF-A and -B; the growth
factor receptors VEGFRs 1, 2, 3 and PDGFR-a and -b; the
endothelial nitric oxide synthase (eNOS); and the thyrocyte
differentiation markers TSHR, NIS, Tg, and TPO.
Materials and methods
Tissue samples
All human tissue samples used in the study had been col-
lected with full patients’ consent and institutional review
board approval. They included 19 AFTN and the non-tumor
tissues from the contralateral lobe (as respective controls) of
the same patients, living in an area of moderate iodine
deficient supply [10], collected at Tinchi-Pisticci Hospital
(Matera, Italy). The specimens have already been used in
other studies of our group [11, 12] in which genetic
examination had revealed the presence of somatic TSH
receptor mutation in a subgroup of tumors (TSHR-mut
AFTN, n = 9) (Table 1). Immediately after removal, part
of each tissue specimen had been snap frozen in liquid
nitrogen and stored at -80 C for RNA isolation; the rest
was fixed in Bouin’s fixative overnight for histological
studies. Before use, representative sections of the frozen
tissue were cut and examined histologically to confirm the
diagnosis and to avoid the contamination of a normal
sample with nucleic acids from tumor-surrounding tissues.
RNA extraction, cDNA synthesis, and real time PCR
Gene expression analysis was determined by real time
quantitative RT-PCR in a 7900HT Fast Real Time PCR
System (Applied Biosystems, Foster City, CA, USA), as
previously described with minor modifications [13]. Briefly,
specific Assays-on-Demand gene expression products
(Applied Biosystems) for each gene were selected to eval-
uate mRNA levels of angiogenesis-related genes (VEGF-A;
VEGFRs 1, 2, and 3; PDGF-A and -B; PDGFR-a and -b;
eNOS) and thyroid-specific markers of differentiations
(TSHR; NIS; Tg; TPO) in each of the 19 AFTN samples and
in a control group consisting of the corresponding contra-
lateral non-tumor tissue of the patients. The b-actin gene was
used as endogenous reference (Pre-Developed TaqMan
Assay Reagents; P/N 4326315E; Applied Biosystems).
Results, determined by the 2-DDCt method [14], were nor-
malized to corresponding calibrator samples.
Analysis of microvessel and lymphatic vessel densities
and cellular proliferation
Immunohistochemical studies included semiquantitative
assessments of microvessel densities (blood and lymphatic)
Table 1 Somatic TSH receptor
mutations in a subgroup of
AFTNs
The functional activity of these
mutations has been previously
reported [34, 35]
Codon Base
substitution
Amino acid change
1 453 ATG ? ACG Methionine ? isoleucine
2 568 ATC ? TTC Isoleucine ? phenylalanine
3 632 ACC ? ATC Tyrosine ? isoleucine
4 453 ATG ? ACG Methionine ? isoleucine
5 486 ATC ? ATG Isoleucine ? methionine
6 631 TTC ? TTG Phenylalanine ? leucine
7 632 ACC ? ATA Threonine ? isoleucine
8 633 GAC ? TAC Aspartic acid ? tyrosine
9 403 Deleted GAT Deleted aspartic acid
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and proliferation rate. They were performed according to
standard procedures [15] on routinely processed, formalin-
fixed sections from six of the 19 tumors, including the non-
tumor counterparts, analyzed by RTQ-PCR. Microvessel
density (MVD) was assessed with a commercial antibody
(Cell Marque, Rocklin, CA, USA) that recognizes the
CD31 marker expressed by endothelial cells of blood and
lymphatic vessels. Microscopic assessment of lymphatic
vessel density (LVD) was done with the Cell Marque’s
mouse monoclonal antibody clone D2-40, which recog-
nizes podoplanin, a marker specific for lymphatic endo-
thelial cells. Cellular proliferation was assessed with the
anti-human Ki67 Antigen (Clone MIB-1) (DAKO, Glost-
rup, Denmark). Immunostaining for CD31, D2-40, and
Ki67 was performed with a BenchMark XT automated
platform (Ventana Medical Systems, Tucson, AZ) by
means of a biotin-free horseradish peroxidase polymer
detection method (Ultravision LP, LabVision Corporation,
Fremont, CA, USA). Labeling in tumors and adjacent non-
neoplastic thyroid tissue was rated as follows. The Weidner
protocol, with minor modifications, was used to determine
MVD and LVD [15]. Individual vessels were counted at
high power (2009), and the averages of the counted vessels
were scored as 1(\30 vessels), 2 (30–60 vessels), 3 ([60
vessels) for CD31, as 1(\5 vessels) and 2 (5–20 vessels), 3
([20 vessels) for D2-40. The Ki67 labeling index (i.e., the
percentage of cells with positive Ki67 nuclear immunore-
activity) was used to determine cellular proliferation, fol-
lowing previously published protocols [16].
Statistical analysis
Quantitative RT-PCR results are expressed as mean ± SD,
and the significance of differences was assessed by the
Mann–Whitney nonparametric test, P values \0.05 were
regarded as statistically significant. Data analysis was
performed by means of StatView 5.0.1 software (SAS
Institute Inc., Cary, NC, USA).
Results
Immunohistochemical analysis of pro-angiogenic
protein expression and vessel densities
Six samples representative of the two subgroups of tumors
(TSHR-mut and TSHR-wt AFTNs) were analyzed by
immunohistochemistry using CD-31, D2-40, and Ki67 as
markers of vessel density and proliferation rate. Results are
summarized in Table 2 and illustrated in Fig. 1. As
expected, Ki67 staining demonstrated proliferating neo-
plastic cells, with variable labeling indexes (range 2–6 %),
but always higher than the corresponding non-tumor one,
in the samples analyzed for gene expression analysis (see
below). All AFTNs exhibited numerous CD31-positive
intra-tumor microvessels (Fig. 1) with consistently higher
MVD scores for toxic adenomas compared with controls.
D2-40 immunostaining demonstrated the network of lym-
phatic vessels in the non-neoplastic thyroid parenchyma.
However, inside the adenoma, lymphatic vessels were
virtually absent with markedly reduced LVD scores com-
pared with controls.
No significant differences appeared between specimens
belonging to each subgroup of mutated or non-mutated
samples for all the markers examined (data not shown).
Gene expression analysis
A series of 19 AFTN tissues were analyzed for the
expression level of major pro-angiogenic factors by real
time quantitative PCR. Compared with the non-tumor tis-
sues, the AFTNs displayed significantly higher mean
mRNA levels for all the growth factors VEGF-A, PDGF-A
and PDGF-B, the receptor VEGFR1, 2, and the eNOS and
not significantly different mean levels of VEGFR3 and
PDGFR-a and -b (Fig. 2a). Subgroup analysis of the
AFTNs showed that transcription of PDGFR-b and eNOS
was significantly higher in the TSHR-mut tumors (Fig. 2b).
Analysis of the expression of the thyrocyte differentia-
tion markers showed a significant increase in the mRNA
levels of NIS, TPO, and Tg, but not the TSHR in the AFTN
compared with their normal counterpart (Fig. 3a). TSHR-
mut subgroup showed TPO mRNA levels significantly
higher than TSHR-wt subgroup (Fig. 3b).
Discussion
Vascularization is fundamental for supporting tumor cell
growth rate and, in case of malignancy, also metastatic
diffusion. Thus, the mechanisms underlying this process
have been the object of investigation for all epithelial
tumors including thyroid ones. Many studies have reported
the presence of endothelial cell proliferation in thyroid
tumors being associated to increased expression of pro-
angiogenic factors; therefore, identification of the profile of
pro-angiogenic factors expressed and their relationship
with other tumor biomarkers may help to provide novel and
additional therapeutic targets. Indeed, many preclinical
studies have been performed and clinical trials are in pro-
gress using novel small molecules provided with anti-
angiogenic activity [17–19].
While many data are available regarding such an
important issue in thyroid malignancies, only few studies
have investigated the mechanism responsible for the
increased vascularization occurring in AFTNs and their
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relationship with the pathogenic alterations detected in
these tumors. Our present data demonstrate the presence of
an increased expression of the pro-angiogenic factors
PDGFs and VEGF with their receptor 1 and 2, associated
with an enhanced proliferation of hematic, but not lym-
phatic, vessels. An upregulation of VEGF-A is a well-
known characteristic of thyroid proliferative lesions
including benign and malignant lesions and Graves’
Table 2 Immunohistochemical analysis of vessel densities and proliferation rate
Case CD31 D2-40 Ki67
2 T 3 1 2
N 1 2 \1
9 T 2 1 5
N 1 2 \1
11 T 2 1 4
N 1 3 \1
12 T 3 1 6
N 1 3 \1
15 T 2 1 3
N 1 2 \1
16 T 3 1 2
N 1 2 \1
The average vessel counts scored at 2009 magnification are rated as follows: 1(\30 vessels), 2 (30–60 vessels), 3 ([60 vessels) for CD31; 1(\5
vessels), 2 (5–20 vessels), 3 ([20 vessels) for D2-40. The Ki67 labeling index is the percentage of cells with positive Ki67 nuclear immuno-
reactivity. Cases 2 and 9 belong to TSHR-mut subgroup. Cases 11, 12, 15, 16 belong to TSHR-wt subgroup
T tumor, N non-neoplastic tissue
Fig. 1 Vessel density and proliferation in AFTN and corresponding
normal control. Hematoxylin and eosin section of a representative
case of AFTN (a) and of surrounding non-tumor tissue (b) (9200);
the endothelial cells of numerous small-sized blood vessels stained
brown after immunohistochemistry for CD31 (c); the corresponding
normal thyroid parenchyma shows fewer capillary vessels than the
tumor (d); brown D2-40 immunostain for lymphatic endothelial cells
is virtually absent in the tumor (e), but present in the non-tumor tissue
(f); red nuclear immunoreactivity for the proliferation marker Ki67 is
present in scattered neoplastic cells (g), but absent in the surrounding
non-tumor tissue (h)
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disease [7, 20, 21]. Also, expression of VEGF-A has been
shown in vitro to be regulated using TSH, via cAMP and
PKC pathways, and Graves’ serum [22, 23]. Our study,
which for the first time compared the mRNA levels of the
AFTN with the corresponding normal tissues, confirms a
role for VEGF to promote neovascularization as support for
the tissue growth and function. Accordingly, and concor-
dant with the results of Deleu et al. [24], increased Ki-67
staining (marker of cell proliferation) paralleled that of
CD-34 used for evaluation of MVD. Also, in accordance
with the data of Viglietto et al. [20] on Graves’ tissues,
expression of VEGF receptors 1 and 2 genes resulted
increased in our series of tissues. Thus, the VEGF-related
pathway appears as a major effector for the vascularization
of toxic adenomas as in thyroid cancer. Moreover, for the
first time, our data showed increased mRNA levels of both
the isoforms of PDGF in the tumors versus the normal
tissues, not correlated with those of the correspondent
receptors. The contribution of such an additional pathway,
previously demonstrated in thyroid cancer [15], remains to
be clarified. Intra-tumor lymphatics development has been
shown to occur in papillary thyroid cancer and is associated
to the presence of nodal metastases [7, 25]. This feature
was absent in our series of benign tumors, appearing
therefore as a clear marker of malignancy. At variance with
our present finding and those of Deleu et al. [24], Viacava
et al. [8] found very low proliferative activity in 15 func-
tioning adenomas compared with adjacent tissue. The well-
known heterogeneity in the clinicobiological behavior of
the AFTNs may, in part, account for such a discrepancy,
especially for a marker expressed at very low levels in
proliferating thyrocytes [16].
A relationship between eNOS expression and vascular
control during goiter formation and hyperthyroidism has
been already reported, including in tissues obtained from
seven patients with Graves’ disease and one with severe
hyperthyroidism due to a germline mutation of the TSH
receptor [26, 27]. Our present data obtained in a larger
series of patients confirm such finding, proposing a role for
NO as a vascular relaxing factor in proliferative and
hyperfunctioning tissues. However, the activation of the
NO pathway in concert with angiogenic factors has been
described also in papillary thyroid carcinomas [28].
Investigation of the expression of the thyrocyte differ-
entiation markers showed an expected increase in the
mRNA levels of NIS, TPO, and Tg, consistent with the
well-differentiated phenotype of these tumors and their
increased rate of hormone synthesis. Also, the finding of a
lack of significant difference in the TSHR gene expression
between tumor and normal tissues was in some way
expected since its constitutive activity (in the mutated
samples) or unknown alterations presumably acting with a
similar molecular mechanism (in the non-mutated samples)
Fig. 2 mRNA levels of genes encoding pro-angiogenic factors.
VEGF-A, VEGFRs 1, 2, and 3, PDGF-A and -B, PDGFR-a and -b,
eNOS mRNA levels were measured in 20 AFTN samples and in a
control group consisting of the corresponding contralateral non-tumor
tissue of each patient (considered as 1) (a) and in TSHR-mut versus
TSHR-wt subgroup (considered as 1) (b). Total RNA was extracted as
described in the ‘‘Methods’’ section. b-actin was amplified as an
endogenous control. Results are expressed as the mean ± SD.
Intergroup differences were assessed by the Mann–Whitney nonpara-
metric test. *P \ 0.05
Fig. 3 mRNA levels of genes encoding thyroid differentiation
markers. NIS, TSHR, TG, and TPO mRNA levels were measured in
20 AFTN samples and in a control group consisting of the
corresponding contralateral non-tumor tissue of the patients (consid-
ered as 1) (a) and in TSHR-mut versus TSHR-wt subgroup (b). All
values are mean ± SD. Intergroup differences were assessed by the
Mann–Whitney nonparametric test. *P \ 0.05
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make an increase of its expression levels not necessary to
get a stimulation of both growth and function of the tumor.
A comparison between AFTN with and without TSHR
mutation revealed very few significant differences in the
expression of genes involved in angiogenesis (PDGFR-b
and eNOS) or differentiation (TPO). A proposed explana-
tion may relate to the above-mentioned unknown altera-
tions present in the TSHR-wt subgroup, which likely
involve the same signal transduction pathways (cAMP or
Ca-IP dependent) constitutively activated in the mutated
group. Alternatively, activation of ‘‘internal feedback
loops’’ in the TSHR-mut subgroup, involving adenylate
cyclase, phosphodiesterase, or functional CREB expres-
sion, may counteract the effects of the mutations [29–31].
Finally, a role for environmental factors in addition to the
genetic alterations may largely influence the gene expres-
sion profile as it acts on the full phenotype of the disease,
as previously documented [32].
Recently, novel drugs provided with anti-angiogenic
effects, mediated in large part by blocking the activation of
receptors for VEGF and PDGFs expressed on endothelial
cells, were under investigation against thyroid malignancy
[33]. Thus, selection of AFTNs expressing high levels of
these proteins may be potential targets of such novel
treatments.
In conclusion, these data demonstrate that increased
expression of vascular growth factors is associated with an
enhanced proliferation of hematic, but not lymphatic,
vessels. In this context, the presence of TSH receptor
mutations may only slightly influence the expression of
growth factors only at transcription levels.
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